Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 2Thoracic 1Gynecologic 1Gastrointestinal 1Endocrine 1Dermatologic 1CNS 1

Conditions

Ovarian Neoplasms 7Colorectal Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Pancreatic Neoplasms 2Neoplasms by Site 2Neoplasms 2Melanoma 2Fallopian Tube Neoplasms 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1Thyroid Cancer, Papillary 1Thoracic Neoplasms 1Skin Neoplasms 1Sarcoma 1Respiratory Tract Neoplasms 1Respiratory Tract Diseases 1Prostatic Neoplasms 1Noonan Syndrome 1Neoplasms, Squamous Cell 1Neoplasms by Histologic Type 1Multiple Myeloma 1Lung Neoplasms 1Lung Diseases 1Laryngeal Neoplasms 1Hematologic Neoplasms 1Glioma 1Glioblastoma 1

Interventions

pembrolizumab 5Magnetic Resonance Spectroscopy 4Trastuzumab 3Nivolumab 3ulixertinib 2palbociclib 2lenvatinib 2belinostat 2Sunitinib 2Specimen Handling 2Fluorodeoxyglucose F18 2FAPI-46 2trastuzumab deruxtecan 1trastuzumab biosimilar HLX02 1trametinib 1tislelizumab 1tipifarnib 1spartalizumab 1sargramostim 1sapanisertib 1relatlimab 1pertuzumab 1pazopanib 1osimertinib 1omipalisib 1olaparib 1methyl N-acetylsibirosaminide 1larotrectinib 1ipatasertib 1erdafitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Thyroid Neoplasms × cobimetinib × Gynecologic × Clear all
NCT04190628 2024-05-21

Safety and Tolerability of ABM-1310 in Patients With Advanced Solid Tumors

ABM Therapeutics Corporation

Phase 1 Terminated
53 enrolled
CNSDermatologicGastrointestinalGynecologicHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Glioblastoma, Melanoma, Ovarian Neoplasms, Thyroid Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡